Jump to content

Xgeva v Zometa? Pain & Quality of Life

Paul Edwards

Recommended Posts

Patients with castration-resistant prostate cancer and bone metastases may experience debilitating pain that impacts daily functioning and diminishes the quality of life.


Previous results from a phase III trial demonstrated superiority of Denosumab (brand name Xgeva) to Zoledronic Acid (brand name Zometa) in delaying or preventing
skeletal-related events (pathological fracture, radiation or surgery to the bone, spinal cord compression) in castration-resistant prostate cancer patients with bone metastases.


Participants in this trial regularly completed Pain Inventory and Quality of Life questionaiires.


Researchers did an ad hoc analysis of this trial which focused on the subgroup of men with no or mild pain at the start of the trial.


This analysis showed that that Denosumab therapy significantly delayed the time to worsening of pain interference and maintained a higher overall cancer specific quality of life compared to Zoledronic Acid in castration-resistant prostate cancer patients with bone metastases.


Should you be having Denosumab instead of Zoledronic Acid? 


I agree with Joel Nowak that you should "Speak with your doctor about this question.”


Previous posts about Denosumab v Zoledronic Acid are at





Link to comment
Share on other sites


This topic is now archived and is closed to further replies.

  • Create New...